-

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company’s growth trends, new patient starts, business outlook, and related operating metrics.

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX).

Share

Beta Bionics Investors: Suffered Losses? Contact Johnson Fistel

If you purchased Beta Bionics securities and suffered losses, you may have legal rights. Investors are encouraged to join the investigation by visiting:

Click Here to Join the Investigation.

For more information, contact James Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to participate.

Why Is Johnson Fistel Investigating Beta Bionics?

The Beta Bionics investigation focuses on investor losses following the Company’s disclosure of slower new patient start growth for the fourth quarter of 2025. New patient starts are an important operating metric for Beta Bionics, and investors may have relied on the Company’s growth trends and public statements when evaluating the Company’s business prospects.

On January 8, 2026, Beta Bionics announced preliminary, unaudited financial results and key operating metrics for the fourth quarter of 2025. The Company reported that new patient starts were expected to be at least 5,581 for the quarter, representing year-over-year growth of at least 36%.

Despite the reported growth, the results were below reported analyst expectations and reflected a significant deceleration from the prior quarter, when Beta Bionics reported 68% year-over-year growth in new patient starts.

If you suffered losses in Beta Bionics securities, you are encouraged to contact Johnson Fistel to discuss your legal rights.

About Johnson Fistel, PLLP

Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder class actions and derivative lawsuits.

Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.

Attorney Advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contacts

Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101

James Baker, Investor Relations
Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com | fjohnson@johnsonfistel.com

Johnson Fistel, PLLP

NASDAQ:BBNX

Release Versions
$Cashtags

Contacts

Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101

James Baker, Investor Relations
Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com | fjohnson@johnsonfistel.com

More News From Johnson Fistel, PLLP

Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors. What if I purchased Capricor securities? If you purchased Capricor securities and suffered losses on your investment, you may join our investigation now: Click Here to Join the Investigation. Or...

HYLN Investor Notice: Johnson Fistel Investigates Hyliion Holdings Corp.

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating Hyliion Holdings Corp. (NYSE American: HYLN) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.What Should Hyliion Investors Do?If you purchased Hyliion securities and suffered losses on your investment, you are encouraged to contact Johnson Fistel to learn more about the investigation.To join the investigation click here.For more information, contact Jim Baker at...

Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company’s financial outlook, reporting practices, internal controls, and related accounting matters. Simulations Plus Investors: Contact Johnson...
Back to Newsroom